Home›Oncology› Hypoxia-inducible factor 1 alpha promotes aggressive phenotypes and treatment resistance in cervical cancer
Hypoxia-inducible factor 1 alpha promotes aggressive phenotypes and treatment resistance in cervical cancerHIF Factors Linked to Aggressive Cervical Cancer Growth
Frontiers in MedicinePublished September 12, 2026Study authors: Yenddy N. Carrero, Jesús A. MosqueraDOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that HIF-1α promotes angiogenesis, invasion, and resistance to radiotherapy and chemotherapy in cervical cancer.
This narrative review synthesizes the role of hypoxia-inducible factor (HIF) and specifically HIF-1α in the progression of cervical cancer and cervical intraepithelial neoplasia. The authors argue that HIF serves as a key inducer of aggressive phenotypes, including angiogenesis, invasion, epithelial-mesenchymal transition (EMT), and modulation of the immune microenvironment. Furthermore, the review highlights that HIF-1α is involved in the expression of genes related to apoptosis, progression, and pro-angiogenic factors such as VEGF, PGF, PDGF-β, PAI-1, MMP-2, MMP-9, ANG-1, and ANG-2.
The review identifies several specific genes associated with HIF-1α expression, including GLUT1, uPAR, BIRC5, EPO, EpoR, LIMD1, VHL, and MET. These factors contribute to the development of resistance to standard treatments like radiotherapy and chemotherapy. The authors note that characterizing hypoxia signatures and evaluating HIF-1α pathway inhibitors are promising strategies for optimizing clinical outcomes.
A primary limitation noted by the authors is that specific clinical trials are still required to validate the impact of HIF-1α pathway inhibitors on patient survival and safety. Current evidence remains focused on the biological mechanisms of the HIF pathway rather than established clinical protocols.
How this fits prior evidence
This narrative review addresses a gap in the understanding of molecular drivers of treatment resistance in cervical cancer. While prior coverage has identified Brucea javanica oil emulsion as an adjunctive agent to reduce chemoradiotherapy side effects, this review focuses on the underlying role of HIF-1α in promoting resistance to radiotherapy and chemotherapy. It complements existing knowledge on cervical cancer management by identifying potential molecular targets for improving outcomes.
This review looked at how hypoxia-inducible factors, specifically HIF-1α, affect the progression of cervical cancer and related conditions. These proteins are known to play a major role in how cancer cells behave and grow in low-oxygen environments.
Researchers found that HIF-1α is linked to several aggressive traits. These include the growth of new blood vessels, the ability of cancer to invade nearby tissues, and the development of resistance to common treatments like chemotherapy and radiotherapy. The study also noted that these factors can change the immune environment around the tumor.
While these findings are promising for developing new treatment strategies, the evidence is currently based on a narrative review. Because this is not a clinical trial, the results do not yet prove how these findings will work in patients. More clinical trials are needed to confirm the safety and effectiveness of targeting these pathways in people with cervical cancer.
What this means for you:
HIF-1α is linked to aggressive cancer traits, but more clinical trials are needed to confirm treatment impacts.
Common questions
What is the role of HIF-1α in cervical cancer?
HIF-1α is linked to several aggressive traits in cervical cancer. It is involved in the expression of genes related to the growth of new blood vessels, cell death, and cancer progression. It also contributes to the ability of cancer to invade tissues and resist treatments like chemotherapy and radiotherapy.
How does HIF-1α affect cancer treatment?
The study indicates that HIF-1α is linked to resistance against radiotherapy and chemotherapy. It also influences the immune microenvironment and the epithelial-mesenchymal transition. Because of these links, researchers are looking at HIF-1α pathway inhibitors as a way to improve treatment outcomes.
Is targeting the HIF pathway a proven treatment for cervical cancer?
Not yet. While the study shows that identifying hypoxia signatures and targeting the HIF-1α pathway are promising tools for optimizing outcomes, specific clinical trials are still needed to validate the safety and impact on patient survival.
Cervical cancer represents a global public health problem, hence the importance of optimizing therapeutic options and expanding knowledge of prognostic markers. Clinical and experimental evidence shows that hypoxia-inducible factor (HIF) is a key inducer of aggressive phenotypes in cervical cancer: promoting angiogenesis, invasion, epithelial-mesenchymal transition (EMT), modulation of the immune microenvironment, and contributing to resistance to radiotherapy/chemotherapy in a possible synergistic effect with the human papilloma virus oncogenes. Hypoxic microenvironments that modulate the early activation of HIF pathways may be present in pre-invasive lesions and favor the acquisition of invasive phenotypes that precede invasion. This review highlights the mechanisms of HIF-1α in the progression of cervical intraepithelial neoplasia and cervical cancer. In this regard, HIF-1α is involved in the expression of genes related to angiogenesis, apoptosis and progression such as GLUT1, uPAR, BIRC5, EPO, EpoR, LIMD1, VHL, MET and pro-angiogenic genes (VEGF, PGF, PDGF-β, PAI-1, MMP-2, MMP-9, ANG-1, ANG-2, using pathways such as YAP/TA2. However, the balance between antitumor factors (miR-143) and protumor factors can define the progression of this neoplasia. In the future, the characterization of hypoxia signatures and the evaluation of HIF-1α pathway inhibitors are promising tools for optimizing outcomes in the treatment of cervical cancer, integrated with modern, high-precision radiation therapy techniques and predictive models based on imaging and artificial intelligence, which represent a key pillar of personalized oncology in cervical cancer, with the potential to improve tumor control and reduce toxicity; however, specific clinical trials are still needed to validate their impact on survival and safety.
